MindWalk Holdings Corp. (NASDAQ:HYFT) Stock Has Average Price Target of $5.00

Shares of MindWalk Holdings Corp. (NASDAQ:HYFT) have earned an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $5.00.

A number of equities analysts have weighed in on the stock. Weiss Ratings raised shares of MindWalk from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. HC Wainwright restated a “buy” rating on shares of MindWalk in a research note on Monday, July 20th. Zacks Research raised MindWalk from a “strong sell” rating to a “hold” rating in a research report on Monday, September 21st. Finally, Wall Street Zen upgraded MindWalk from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

MindWalk Price Performance

Shares of HYFT stock opened at $1.06 on Monday. The firm has a fifty day simple moving average of $1.30 and a 200-day simple moving average of $1.38. The company has a market capitalization of $50.43 million, a PE ratio of -4.08 and a beta of 0.79. MindWalk has a twelve month low of $0.98 and a twelve month high of $2.99. The company has a current ratio of 1.84, a quick ratio of 1.75 and a debt-to-equity ratio of 0.43.

MindWalk (NASDAQ:HYFT) last released its quarterly earnings results on Monday, September 14th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04). MindWalk had a negative return on equity of 133.26% and a negative net margin of 105.11%. The firm had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $3.25 million. Equities research analysts anticipate that MindWalk will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MindWalk

A hedge fund recently bought a new stake in MindWalk stock. BlackRock Inc. bought a new stake in MindWalk Holdings Corp. (NASDAQ:HYFT) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 154,411 shares of the company’s stock, valued at approximately $244,000. BlackRock Inc. owned approximately 0.33% of MindWalk as of its most recent SEC filing. 6.70% of the stock is owned by institutional investors.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.